CD274 and neoplasm: In the same study, it was observed that SIGLEC-15 can facilitate immune escape in PD-L1-knockout tumors, and combining anti-SIGLEC-15 with anti-PD-1 resulted in better tumor control in mouse models compared to using either alone [15].